Phraxis

Focus: Phraxis is a medical device biotechnology company focused on vascular access devices for hemodialysis patients, addressing a critical unmet need in nephrology and cardiovascular care.

Cardiovascular Nephrology

Profile data last refreshed Yesterday · AI intelligence enriched 2w ago

Open Jobs

About Phraxis

AI assessmentNot Hiring

No open roles listed right now. Follow Phraxis to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

1/9 — Limited

Company HealthSolid

Pipeline

Early-stage

3 total

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

VIG Continued Access Study

Dialysis Access Malfunction

N/A

Clinical Trials (1)

NCT05448950Continued Access Study VIG Anastomotic Connector

N/A

Help build intelligence for Phraxis

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Focused pipeline in high-need therapeutic areas (nephrology/cardiovascular) with three active post-approval and continued access studies providing near-term clinical momentum
Specialized medical device focus offers distinct career path in device development and regulatory strategy vs. traditional pharma
St. Paul headquarters provides access to Midwest biotech ecosystem with lower cost of living than coastal hubs

Watch Out For

Zero active job openings and no disclosed employee count suggest company may be pre-commercial or in holding pattern operationally
No disclosed funding, revenue, or financial metrics create uncertainty about company stability and growth trajectory
Limited pipeline depth (3 programs, all post-approval/continuation phases) offers fewer catalyst opportunities vs. traditional development-stage biotech

Generated by Claude from Phraxis's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

EndoForce Post Approval Study

End Stage Renal Disease (ESRD)

N/A

Clinical Trials (1)

NCT07146854EndoForce Post Approval Study

N/A

Venous InterGraft Connector

End Stage Renal Disease

N/A

Clinical Trials (1)

NCT02532621Clinical Evaluation of a Vascular Venous Anastomotic Connector [InterGraft VIG-only Study]

N/A

Open Jobs (0)

No open positions listed yet. Check their careers page directly.

Interview Prep Quick Facts

Portfolio: 3 clinical trials

Top TAs: Nephrology

Pro Feature

Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.

Upgrade to Pro — $25/mo

Therapeutic Area Focus

Nephrology

3 pipeline

Marketed

Pipeline